Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.

Lotfi, M; Morshedi Rad, D; Mashhadi, SS; Ashouri, A; Mojarrad, M; Mozaffari-Jovin, S; Farrokhi, S; Hashemi, M; Lotfi, M; Ebrahimi Warkiani, M; Abbaszadegan, MR

Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.

Lotfi, M Morshedi Rad, D Mashhadi, SS Ashouri, A Mojarrad, M Mozaffari-Jovin, S Farrokhi, S Hashemi, M Lotfi, M Ebrahimi Warkiani, M

Abbaszadegan, MR

Permalink

Publisher:: SPRINGER
Publication Type:: Journal Article
Citation:: Stem Cell Rev Rep, 2023, 19, (8), pp. 2576-2596
Issue Date:: 2023-11

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.69 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Lotfi, M
dc.contributor.author	Morshedi Rad, D
dc.contributor.author	Mashhadi, SS
dc.contributor.author	Ashouri, A
dc.contributor.author	Mojarrad, M
dc.contributor.author	Mozaffari-Jovin, S
dc.contributor.author	Farrokhi, S
dc.contributor.author	Hashemi, M
dc.contributor.author	Lotfi, M
dc.contributor.author	Ebrahimi Warkiani, M https://orcid.org/0000-0002-4184-1944
dc.contributor.author	Abbaszadegan, MR
dc.date.accessioned	2024-02-05T23:18:33Z
dc.date.available	2023-06-30
dc.date.available	2024-02-05T23:18:33Z
dc.date.issued	2023-11
dc.identifier.citation	Stem Cell Rev Rep, 2023, 19, (8), pp. 2576-2596
dc.identifier.issn	2629-3269
dc.identifier.issn	2629-3277
dc.identifier.uri	http://hdl.handle.net/10453/175325
dc.description.abstract	Rapid advancement in genome editing technologies has provided new promises for treating neoplasia, cardiovascular, neurodegenerative, and monogenic disorders. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has emerged as a powerful gene editing tool offering advantages, including high editing efficiency and low cost over the conventional approaches. Human pluripotent stem cells (hPSCs), with their great proliferation and differentiation potential into different cell types, have been exploited in stem cell-based therapy. The potential of hPSCs and the capabilities of CRISPR/Cas9 genome editing has been paradigm-shifting in medical genetics for over two decades. Since hPSCs are categorized as hard-to-transfect cells, there is a critical demand to develop an appropriate and effective approach for CRISPR/Cas9 delivery into these cells. This review focuses on various strategies for CRISPR/Cas9 delivery in stem cells.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	SPRINGER
dc.relation	http://purl.org/au-research/grants/arc/DP200101860
dc.relation.ispartof	Stem Cell Rev Rep
dc.relation.isbasedon	10.1007/s12015-023-10585-3
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	31 Biological sciences
dc.subject.mesh	Humans
dc.subject.mesh	CRISPR-Cas Systems
dc.subject.mesh	Gene Editing
dc.subject.mesh	Pluripotent Stem Cells
dc.subject.mesh	Cell Differentiation
dc.subject.mesh	Stem Cell Transplantation
dc.subject.mesh	Pluripotent Stem Cells
dc.subject.mesh	Humans
dc.subject.mesh	Stem Cell Transplantation
dc.subject.mesh	Cell Differentiation
dc.subject.mesh	CRISPR-Cas Systems
dc.subject.mesh	Gene Editing
dc.subject.mesh	Humans
dc.subject.mesh	CRISPR-Cas Systems
dc.subject.mesh	Gene Editing
dc.subject.mesh	Pluripotent Stem Cells
dc.subject.mesh	Cell Differentiation
dc.subject.mesh	Stem Cell Transplantation
dc.title	Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells.
dc.type	Journal Article
utslib.citation.volume	19
utslib.location.activity	United States
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2024-02-05T23:18:29Z
pubs.issue	8
pubs.publication-status	Published
pubs.volume	19
utslib.citation.issue	8

Abstract:

Rapid advancement in genome editing technologies has provided new promises for treating neoplasia, cardiovascular, neurodegenerative, and monogenic disorders. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system has emerged as a powerful gene editing tool offering advantages, including high editing efficiency and low cost over the conventional approaches. Human pluripotent stem cells (hPSCs), with their great proliferation and differentiation potential into different cell types, have been exploited in stem cell-based therapy. The potential of hPSCs and the capabilities of CRISPR/Cas9 genome editing has been paradigm-shifting in medical genetics for over two decades. Since hPSCs are categorized as hard-to-transfect cells, there is a critical demand to develop an appropriate and effective approach for CRISPR/Cas9 delivery into these cells. This review focuses on various strategies for CRISPR/Cas9 delivery in stem cells.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175325